CAMBRIDGE, MA October 29, 2021 – Flatiron Health®, a world leader in transforming patients’ real-life experiences into knowledge to help accelerate improvements in cancer care and treatments, has joined the Massachusetts Institute of Technology Center for Biomedical Innovation’s New Drug Development Paradigms (NEWDIGS) initiative.
Flatiron Health will collaborate in the Learning Ecosystems Accelerator for Patient-centered, Sustainable Innovation (LEAPS) project. LEAPS was launched in 2018 to advance the knowledge and practice of precision medicine by modernizing how we plan, produce, and use real-world evidence (RWE). Multi-stakeholder collaborators work together in LEAPS to design and pilot new, scalable RWE production platforms and payment models that improve the use of targeted drug therapy regimens.
“We are excited to work with NEWDIGS on innovative and cross-cutting initiatives that advance the impact of RWE in novel ways for patients,” said Irene Nunes, OD, PhD, Vice President of Regulatory Affairs at Flatiron Health.
“We welcome Flatiron Health as an important thought partner and collaborator for NEWDIGS,” said Gigi Hirsch, MD, Executive Director of NEWDIGS.
Flatiron Health is a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients today and tomorrow. Through clinical and data science, we translate patient experiences into real-world evidence to improve treatment, inform policy, and advance research. Flatiron Health is an independent affiliate of the Roche Group. For more information, visit www.flatiron.com and follow @FlatironHealth.
MIT NEW Drug Development ParadIGmS (NEWDIGS) is an international “think and do tank” dedicated to delivering more value faster to patients, in ways that work for all stakeholders. NEWDIGS designs, evaluates, and catalyzes the real-world implementation of system innovations that are too complex and cross-cutting to be addressed by a single organization or market sector. Its members include global leaders from patient advocacy, payer organizations, biopharmaceutical companies, regulatory agencies, clinical care, academic research, and investment firms. For more information, visit http://newdigs.mit.edu.
The MIT NEWDIGS LEAPS Project advances the knowledge and practice of Precision Medicine by modernizing how we Plan, Produce, and Use real-world evidence (RWE). We take a systems approach to enhancing the efficiency and scalability of real-world learning to ensure that the right drug therapies are delivered to the right patient at the right time. Our participatory design approach involves stakeholders in the system who hold the data, use the evidence, and only together have the power to ensure that healthcare is both patient-centered and economically sustainable. For more information, visit https://newdigs.mit.edu/programs-projects/leaps
Flatiron Health Contact
MIT NEWDIGS Contact